|Bid||74.83 x 1000|
|Ask||75.29 x 800|
|Day's Range||73.68 - 75.22|
|52 Week Range||34.72 - 107.69|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.83|
FRIENDSWOOD, Texas, Jun 21, 2021--Castle has been included in the Houston Chronicle’s list of the 100 most successful publicly traded companies in the Houston area.
Castle announced that it has received approval from the New York State Department of Health for its DecisionDx-SCC test.
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Baird 2021 Healthcare ESG Symposium on June 17, 2021, at 11:20 a.m. Eastern time.